Teva/Ivax Merger Gets FTC OK Pending Divestitures
This article was originally published in The Pink Sheet Daily
Executive Summary
Par and Barr will acquire 15 of the companies’ generic offerings.
You may also be interested in...
Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
Teva Incoming CEO Yanai To Take The Helm In First Half 2007
Teva appoints CEO Makov’s successor, the leader of a generic crop protection chemicals firm, from outside pharma.
Teva Incoming CEO Yanai To Take The Helm In First Half 2007
Teva appoints CEO Makov’s successor, the leader of a generic crop protection chemicals firm, from outside pharma.